1 |
Breitbach, C. J., Parato, K., Burke, J., Hwang, T. H., Bell, J. C. and Kirn, D. H. 2015. Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. Curr. Opin. Virol. 13, 49-54.
DOI
|
2 |
Cruz, P. E., Silva, A. C., Roldão, A., Carmo, M., Carrondo, M. J. and Alves, P. M. 2006. Screening of novel excipients for improving the stability of retroviral and adenoviral vectors. Biotechno.l Prog. 22, 568-576.
DOI
|
3 |
Donnelly, O. G., Errington-Mais, F., Prestwich, R., Harrington, K., Pandha, H., Vile, R. and Melcher, A. A. 2012. Recent clinical experience with oncolytic viruses. Curr. Pharm. Biotechnol. 13, 1834-1841.
DOI
|
4 |
Galdiero, F. 1979. Adenovirus aggregation and preservation in extracellular environment. Arch. Virol. 59, 99-105.
DOI
|
5 |
Kim, M. K., Breitbach, C. J., Moon, A., Heo, J., Lee, Y. K., Cho, M., Lee, J. W., Kim, S. G., Kang, D. H., Bell, J. C., Park, B. H., Kirn, D. H. and Hwang, T. H. 2013. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci. Transl. Med. 5, 185ra63
DOI
|
6 |
Kaufman, H. L., Kohlhapp, F. J. and Zloza, A. 2015. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev. Drug Discov. 14, 642-662.
DOI
|
7 |
Mackett, M., Smith, G. L. and Moss, B. 1982. Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. USA 79, 7,415-7,419.
DOI
|
8 |
Park, B. H., Hwang, T., Liu, T. C., Sze, D. Y., Kim, J. S., Kwon, H. C., Oh, S. Y., Han, S. Y., Yoon, J. H., Hong, S. H., Moon, A., Speth, K., Park, C., Ahn, Y. J., Daneshmand, M., Rhee, B. G., Pinedo, H. M., Bell, J. C. and Kirn, D. H. 2008. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533-542.
DOI
|
9 |
Smith, G. L., Mackett, M. and Moss, B. 1984. Recombinant vaccinia viruses as new live vaccines. Biotechnol. Genet. Eng. Rev. 2, 383-407.
DOI
|
10 |
Verardi, P. H., Titong, A. and Hagen, C. J. 2012. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Hum. Vaccin. Immunother. 8, 961-970.
DOI
|
11 |
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., Burke, J., Lencioni, R., Hickman, T., Moon, A., Lee, Y. S., Kim, M. K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J. C., Rhee, B. G., Patt, R., Hwang, T. H. and Kirn, D. H. 2013. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329-336.
DOI
|